Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

News Conference News ESC 2022

INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF

Michael O'Riordan

August 28, 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

News Daily News

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Michael O'Riordan

July 11, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

News Conference News ACC 2022

Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms

April 02, 2022

April 2022 News Roundup

News Opinion CV Team Dispatch

April 2022 News Roundup

April 01, 2022

More Evidence Links Breast Arterial Calcification and CVD Risk

News Daily News

More Evidence Links Breast Arterial Calcification and CVD Risk

March 15, 2022

March 2022 News Roundup

News Opinion CV Team Dispatch

March 2022 News Roundup

March 01, 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

January 2022 News Roundup

News Opinion CV Team Dispatch

January 2022 News Roundup

January 01, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.